3rd European Congress on
Pharmaceutical Science & Research

Ozan Emre EYUPOGLU is an Assistant Professor at Istanbul Medipol University, School of Pharmacy. He is the Head of the Department of Basic Pharmaceutical Sciences and the Head of the Department of Biochemistry. He received his Ph.D. from Karadeniz Technical University, Institute of Science, Chemistry (Biochemistry) in 2017. Area of interest includes Health Sciences, Medicine, Basic Medical Sciences, Biochemistry, Biophysics, Biomolecules, Nanotechnology, Lipidomics, Proteomics and Biological Spectroscopy. He has published numerous research articles in well-known journals and given international conferences on chromatographic analyzes and antioxidant activities of medicinal plants. He is closely related to topics such as artificial intelligence, machine learning and innovative techniques, and plans studies for processing biochemical data for disease diagnosis. He is an interdisciplinary scientist specializing in developing on-line chromatographic methods. There are 2 national patents, 1 international patent and 1 utility model related to a medical product and a herbal formulation. He advised 2 master's candidates who did thesis on the coagulation system and aromatherapy, and now has 3 doctorate studies on the nanotechnological applications of drugs and herbal extracts, and 1 doctorate working on the toxicology of bee products. As an editor and referee in many national and international journals, Dr. EYUPOGLU is an Associate member of the European Materials Modelling Council and received the 2020 International Young Scientist Award in Engineering, Science and Medicine from the International VDGOOD Technology Company.

Health Sciences, Medicine, Basic Medical Sciences, Biochemistry, Biophysics, Biomolecules, Nanotechnology, Lipidomics, Proteomics and Biological Spectroscopy

Russell Elliott, Ph.D., has served as the Vice President of Drug Development since May 2016. Dr. Elliott has over 25 years of industry experience, previously holding positions as Head of Skincare Technology at Lonza Inc. from 2015 to 2016, Head of Product Development at Stiefel (a GSK Company) from 2011 to 2014, Head of the Center of Excellence for Liquids, Cream and Ointments at GSK (UK) from 2007 to 2011, and Principal Scientist at Procter & Gamble from 1992 to 2007. He has filed more than 60 patent applications in the area of skincare formulation. Dr. Elliott has a PhD and MA from The University of Oxford and is a Fellow of the Royal Society of Chemistry

Drug development

Dr. Rahul R. Panchal is an innovator, entrepreneurial, and savvy business professional with a strong background and experience in the area of medical device development including but not limited to disposable, implantable, surgical, drug delivery devices.he is the founder and president of Leonine Technologies Inc.

He is an inventor of “multivariate shrinkage sensor (MVSS)” technology and currently pursuing the commercial development of MVSS technology under National Science Foundation (NSF)’s small business innovation research (SBIR) grant program.

Dr. Elder has nearly 40 years of service within the pharmaceutical industry (Sterling, Syntex and for the last two decades with GSK). He is now an independent CMC consultant and has broad based experience in excipients, biopharmaceutics, drug product and analytical method development. Dr. Elder obtained his PhD in crystallography from the University of Edinburgh. Dr. Elder is a visiting professor at King’s College, London. He is a member of the British Pharmacopoeia. He is the immediate past chairman of JPAG (Joint Pharmaceutical Analysis Group). He is a member of the Editorial Advisory Board for the Journal of Pharmaceutical Sciences. He has published 114 and presented 17 webinars and 133 presentations. He has co-edited one book on the Analytical Characterization and Separation of Oligonucleotides and their Impurities (with George Okafo and Mike Webb) and is editing a second book on the ICH Quality Guidelines (with Andy Teasdale, AZ).

Dr. Elder has a long standing interest in impurities and degradation chemistry. He has played a leading role in the identification, analysis and control of mutagenic impurities. He has been part of EfPIA and PhRMA sub-groups on mutagenic impurities and the PQRA group that investigated the formation and control strategies for alkyl sulfonate impurities. He is interested in the role that excipients play in stabilising/destabilising molecules and the impact that changes in excipient material attributes can have on processability of drug products. He is interested in biopharmaceutics and its role in devising formulation strategies, as well as the more classical role that biopharmaceutics plays in biowaivers, bioavailability and bioequivalence studies. He is interested in clinically relevant specifications and whether dissolution tests (and related specifications) can ever really be robust enough to be used in a QC environment and sensitive enough to be truly predictive of clinical outcomes.

Amanda Vickers is a medicinal plant chemist, product developer, and entrepreneur, currently directing a botanical testing and formulation lab in North Carolina. Bent Creek Institute is a nonprofit organization, founded to connect conservation-driven botanical research from the Southern Appalachian Mountains to commercialization opportunities in a rapidly expanding global natural products marketplace. In 2012, BCI launched the US Botanical Safety Lab, which has since helped more than sixty companies to propel new innovative natural products to market and clear major regulatory milestones. Amanda is also a founding partner of a natural body care company, Mountains to Sea, which creates opportunities to experience more nature every day through a line of “pure and wild” products produced by an integrated network of horticulturists, conservationists, wild harvesters, small farmers, artisans and makers deeply engaged in exploring new definitions of purity and wilderness in an age of exponential accelerations in technology, connectivity, climate change and human population growth.

Developing trust networks within natural product supply chains.

Dr. Stephen F. Amato has over 25 years of experience in the pharmaceutical, biotechnology and medical device industries. Prior to his position as Faculty Director of Graduate Regulatory Affairs & Life Sciences at Northeastern University, Steve was the Founder and Managing Director of tJun17 Life Sciences, LLC, and also a Managing Director for Cardinal Health Regulatory Sciences (CHRS). As an Executive Director at Anika Therapeutics Steve managed all aspects of the company's product portfolio including regulatory, reimbursement, market segmentation, targeting, positioning, pricing and promotional strategies. From 2000 to 2007 he was the Group Director of Knee Repair at Smith & Nephew Endoscopy where he managed a $140 M orthopedic product portfolio. Earlier in his career, Steve worked for Visible Genetics, where he was responsible for developing and launching genomic molecular diagnostics products used for subtyping Human Papilloma Virus (HPV) and other infectious disease agents. He has also worked with Critical Therapeutics on the development and commercialization of treatments for gram-negative sepsis. Steve holds an AB in Biochemical Sciences from Harvard University, a Ph.D. in Molecular and Cellular Biology from Boston College’s Graduate School of Arts & Sciences, and an MBA from the Carroll School of Graduate Management at Boston College. He has also received the US and EU Regulatory Affairs Certification (RAC) designations and is a Consultant for the Regulatory Affairs Professional Society (RAPS).

Global regulatory affairs

Maria Lazaro is a Pharmacist from Complutense University of Madrid. He/She(according to the author’s gender) holds advanced master’s in Biotechnology and Pharmaceutical Management works for Seppic in Human Biologicals department (adjuvants for vaccines and excipients for injectables ) since 2012.

animal health, vaccine manufacture, vaccine development

Dr Grob is passionate about utilizing technology to empower people to live better and do their jobs better. He has trained in occupational preventative medicine and has functioned as a clinical investigator in multiple pharmaceutical trials. His broad background in medicine, AI predictive analytics, and drug development augment his interest in pharmacovigilance. He obtained a BS in biochemistry from SUNY Stony Brook, and graduate work in public health and economics at SUNY Albany and Harvard before completing his MPH at the University of Minnesota School of Public Health. His expertise in VR and AR is self guided and fueled by coffee

General Surgery

Dr Ian James Martins is an Editor/Reviewer for Open Acess Pub/MDPI journals and various other international journals. Advisory Board Member for Photon Journal. Fellow of International Agency for Standards and Ratings (IASR). Conferred with the RICHARD KUHN RESEARCH AWARD-2015 ENDOCRINOLOGY AND METABOLISM. Chief Editor for International Journal of Diabetes Research (2014-2018), Research and Reviews: Neuroscience (2016-2018) and Journal of Diabetes and Clinical Studies (2017-2018). BIT Member (BIT Congress. Inc) with an h-index of 65, (ResearchGate STATs (28), Scopus Author ID: 7103152779/Mendeley STATS (21), UWA Research Repository (16). Scientist for The Science Advisory Board (USA) and an Academic with Academia.edu (220 Public Mentions). The citations past 27 years have accumulated to >4770. Ian James Martins - Semantic Scholar Profile https://www.semanticscholar.org/author/Ian-James-Martins/5258067. Semantic Scholar profile for Ian James Martins, with fewer than 133 highly influential citations RESEARCHGATE ANALYSIS: Ian J Martins | Ph D | Centre of Excellence for Alzheimer's Disease ...https://www.researchgate.net/profile/Ian_Martins2 under Ian James Martins’ name places publication Research Interest (1622) with an RG score (> 96%) of international SCIENTISTS. ORCID CONNECTING RESEARCHER: Editorial Team www.macrothink.org/journal/index.php/jfs/about/editorialTeamBio/13511 Editorial Team.

Anti-Aging, Global Health and Chronic Disease . Keywords: Anti-Aging Genes, Appetite, Environment, Nutrition, Senescence IMPACT OF PREVIOUS RESEARCH TO THE FIELD OF MEDICINE AND LABORATORY TECHNOLOGY THAT MAY AVOID INADVERTENT ERRORS AND MAY TRANSLATE TO COMMERCIALISATION OF MEDICAL RESEARCH THAT determines CRITICAL HEALTH OUTCOMES. Development of a BLOOD TEST has been of critical interest to the for metabolic disease with relevance to diabetes and neurodegenerative diseases. Interests in Biomarker Research has escalated with relevance to mitochondrial survival and organ disease in diabetes and Alzheimer’s disease. The global chronic disease epidemic is expected to cost Biomarker Research between 15 to 20 billion dollars in the next 20 years. Biomarkers such as Sirtuin 1 are now relevant to mitochondrial apoptosis versus mitochondrial biogenesis and may supersede the various biomarkers for mitochondrial survival relevant to diabetes, Alzheimer’s disease and neurodegenerative disease research Anti-Aging Genes, Appetite, Environment, Nutrition, Senescence.

Dr. Shin Aoki graduated from the University of Tokyo with B. S. (1986), M.S. (1988), and Ph.D. (1992) degrees in pharmaceutical sciences under the supervision of Prof. Kenji Koga. He started his academic carrier as an assistant professor at the University of Tokyo from 1990. Following postdoctoral positions with Professor Chi-Huey Wong at the Department of Chemistry, the Scripps Research Institute, USA, he joined Prof. Eiichi Kimura’s research group in 1995 at the Faculty of Medicine, Hiroshima University, where he became an associate professor in 2001. In 2003, he has been promoted to a professor at the Faculty of Pharmaceutical Sciences, Tokyo University of Science. He is a recipient of the Award of Japan Society of Coordination Chemistry for Young Scientists (1999), the Pharmaceutical Society of Japan Award for Young Scientists (2002), and so on.

His major research interests are bioorganic chemistry, bioinorganic chemistry, supramolecular chemistry, photochemistry, and medicinal chemistry